What is Amylyx Pharmaceuticals, Inc.'s R&D?

Amylyx Pharmaceuticals, Inc. (AMLX) reported R&D of $27.61M in Q1 2026.

How has Amylyx Pharmaceuticals, Inc.'s R&D changed year-over-year?

Amylyx Pharmaceuticals, Inc.'s R&D increased by 24.8% year-over-year, from $22.12M to $27.61M.

What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s R&D?

Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s R&D has grown at a 19.7% compound annual growth rate (CAGR), from $44.04M to $90.4M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Amylyx Pharmaceuticals, Inc. AMLX R&D

R&D at other companies

MBX Biosciences, Inc.MBX

$18.47M-17.5%

Viking TherapeuticsVKTX

$150.15M+263%

Beam TherapeuticsBEAM

$104.52M+5.8%

Crinetics PharmaceuticalsCRNX

$100.08M+31.3%

Agios PharmaceuticalsAGIO

$81.15M+11.6%

Rhythm Pharmaceuticals, Inc.RYTM

$41.73M+12.9%

Segments

By product

See full

Avexitide$9.99M+84.1%

Other Programs$7.98M+111%

AMX0035PSP$649K-85.8%

Other financials

Income statement

See full

Revenue-—

Gross profit-—

Operating income-$43.8M-15.8%

Net income-$41.3M-15.0%

EPS (diluted)-$0.37+11.9%

Balance sheet

See full

Cash & equivalents$229.1M+283%

Total debt$5.6M+307%

Total equity$273.2M+35.6%

Total assets$293.6M+33.7%

Cash flow

See full

Operating cash flow-$36.9M+7.4%

CapEx$86.0K+330%

Free cash flow-$28.0M+52.6%

Valuation

See full

Market cap$1.82B+390%

Enterprise value$1.6B+414%

Profitability

See full

Gross margin100%+6.9pp

Operating margin-47,349.8%-47,409pp

Net margin-45,096.2%-45,152pp

FCF margin-39,826.7%-39,847pp

Returns & leverage

See full

Return on equity-63.3%-12.2pp

Debt / equity0×0.0×

Current ratio17.9×+5.8×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s R&D?: Amylyx Pharmaceuticals, Inc. (AMLX) reported R&D of $27.61M in Q1 2026.
How has Amylyx Pharmaceuticals, Inc.'s R&D changed year-over-year?: Amylyx Pharmaceuticals, Inc.'s R&D increased by 24.8% year-over-year, from $22.12M to $27.61M.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s R&D?: Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s R&D has grown at a 19.7% compound annual growth rate (CAGR), from $44.04M to $90.4M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.